Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Christine Roy-Duval
Observed names:
C. Roy-Duval,
C. Roy-duval
Institution:
Sanofi (France)
Observed institution:
Sanofi (France)
OpenAlex ID:
A5009161997
Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial
2015
·
Juris J. Meier
, Julio Rosenstock
, et al.
·
Diabetes Care
·
283
Differential effects of glucagon-like peptide-1 receptor agonists on heart rate
2017
·
Martin Lorenz
, Francesca Lawson
, et al.
·
Cardiovascular Diabetology
·
184
PDF
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial
2016
·
Julio Rosenstock
, Bruno Guerci
, et al.
·
Diabetes Care
·
136
Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial
2017
·
Graydon S. Meneilly
, Christine Roy-Duval
, et al.
·
Diabetes Care
·
45
Lixisenatide Therapy in Older Patients with Type 2 Diabetes Inadequately Controlled on Their Current Anti-Diabetic Treatment: The GetGoal-O Study (NCT01798706)
2016
·
Graydon Meneilly
, Hasan Alawi
, et al.
·
Canadian Journal of Diabetes
·
3
Once-Daily Lixisenatide in Combination with Basal Insulin ± Oral Antihyperglycemic Agents in Patients with Type 2 Diabetes Selectively Reduces Postprandial Hyperglycemic Daytime Exposure
2013
·
Harpreet S. Bajaj
, Ricardo Gomez-Huelgas
, et al.
·
Canadian Journal of Diabetes
·
1
PDF
CAD-28: Optimisation de l'utilisation de l'insuline Glargine par l'ajout de lixisénatide prandial vs l'insuline glulisine une fois par jour (GLU-1), ou l'insuline glulisine 3 fois par jour (GLU-3) : GetGoal-Duo2
2016
·
B. Guerci
, M. Hanefeld
, et al.
·
Diabetes & Metabolism
P330 Effets du lixisénatide vs liraglutide sur l’équilibre glycémique, la vidange gastrique et les critères de tolérance du traitement dans le diabète de type 2 (DT2) traité de façon optimisée par insuline glargine ± metformine
2015
·
B. Guerci
, J.J. Meier
, et al.
·
Diabetes & Metabolism
Show more works
View as search
Works count:
8
Citation count:
652
H-index:
4
I10-index:
4
Year
Topic
Type